We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Oncologic Drugs Committee Split on Risk-Benefit Profile of Pfizer Candidate
Oncologic Drugs Committee Split on Risk-Benefit Profile of Pfizer Candidate
An FDA advisory committee deadlocked 6 to 6 on whether the benefits of a Pfizer drug treatment for recurrent renal cell carcinoma outweighed the risks.